The global gastritis treatment market overview describes the market consisting of drug therapies such as proton pump inhibitors (PPIs), potassium-competitive acid blockers (P-CABs), antacids, antibiotics and H2-receptor blockers which provide relief from gastric inflammation and ulceration. Gastritis treatment helps reduce stomach acid production, protects the stomach lining, and fights bacterial infections. The global gastritis treatment market size is estimated to be valued at US$ 131.76 billion in 2024 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030.

Key Takeaways

Key players operating in the gastritis treatment market are Pfizer Inc., AstraZeneca plc, Johnson & Johnson, Novartis AG, Takeda Pharmaceutical Company Limited.

The key opportunities in the market include increasing research funding for developing novel drugs and rising number of acquisitions and collaborations between key companies.

The global gastritis treatment market is expanding rapidly with growth in emerging economies of Asia Pacific and Latin America owing to rising healthcare expenditure and growing awareness.

Market Drivers
The primary driver fueling the gastritis treatment market growth is the rising geriatric population worldwide who are more susceptible to gastritis. Age is a significant risk factor for gastritis as old age can weaken the stomach lining and reduce stomach acid levels. According to the United Nations, the number of people aged 60 years and above is expected to double by 2050 and reach around 2 billion people. This vast geriatric population base will propel the demand for gastritis treatment drugs in the upcoming years.

PEST Analysis
Political: Stringent regulations are imposed on the production and distribution of drugs used for treatment of gastritis. Government policies aim to ensure safety and efficacy of approved drugs.

Economic: Rising healthcare expenditures and increasing demand for over-the-counter drugs to treat recurring gastric problems will boost market revenues. However, price controls affect profits of drug makers.

Social: Changing lifestyles and eating habits resulting in sedentary lifestyle and consumption of junk food are key causes of gastritis. Rise in stress levels also impact digestive health.

Technological: Players focus on development of novel drug delivery systems and combination therapies to improve treatment effectiveness with minimal side effects. Digitization in healthcare enhances access to medical information and virtual consultations.

Geographic Concentration
North America accounts for the largest share of the global gastritis treatment market in terms of value. Rising incidence of gastrointestinal disorders and easy availability of drugs drive market growth in the region. Availability of medical reimbursement further supports market revenues.

Fastest Growing Region
Asia Pacific exhibits the fastest growth and is projected to record a CAGR of around 7% during the forecast period. Increasing healthcare expenditure, large patient pool, and growing awareness about digestive disorders majorly contribute to regional market expansion. Favorable government policies to enhance access to healthcare also support market growth.